Skip 
Navigation Link
Medical Disorders
Resources
Basic InformationLookupsLatest News
Family History Questionnaire Ups Genetic Counseling for CRCBlood Test Can Detect GLUT1 Deficiency SyndromeWallpaper May Breed Toxins: StudyFish Eaters Report Less Rheumatoid Arthritis PainGuided Exercise May Help Chronic Fatigue Patients: Study2006 to 2013 Saw Increase in ER Use for Herpes ZosterNearly 60 Percent With Conjunctivitis Fill Antibiotic RxTissue Testing Can Spot Zika at Birth: CDCGuidelines Address Peri-Op Care in Rheumatic DiseaseZika-Bearing Mosquitoes More Widespread in U.S. Than ExpectedMarital Status Among Factors Tied to Gout Rx AdherenceMany Chronic Illnesses Linked to Suicide RiskVaccine Curbs High Cholesterol in MiceStudy Hints at Link Between Some Statins, Parkinson's RiskHydrotherapy Plus Conventional Drugs Beneficial in RAChronic Lyme Disease Treatments Tied to Serious Adverse EffectsOlder Age Needn't Be a Barrier to Herniated Disc SurgeryNon-Opioid Drug More Effective for Migraines: StudyHealth Tip: Managing Arthritis FatigueCertain Criteria May Be Better Than Others in RA Assessment20 Percent of Hospital Patients Have Side Effects From Abx RxRecreational Activity-Linked Facial Fractures Up in SeniorsUnusual Measles Outbreak Described in Ontario in Early 2015Seniors Get Good Results From Herniated Disc Surgery'Good' Donor Bacteria Can Last Long Term in Stool Transplant PatientsNovel Retinal Lesion Seen in Some Ebola SurvivorsHealth Tip: Recognizing Summer Allergy SymptomsAre You at Risk for Metabolic Syndrome?Antiplatelet Bleeding Risk Higher Than Expected for Older PatientsVideo Call May Be as Good as Doctor Visit for HeadacheCould Prefab Blood Vessels Revolutionize Root Canals?A Sufferer's Guide to Easin' Sneezin' SeasonHospitals Get Good News About Fighting Staph InfectionsCases of Legionnaires' Disease Reported in NYC, Las VegasOlive Oil, Ibuprofen May Have Synergistic EffectsObesity Prevalence Has Doubled in More Than 70 CountriesSeveral New Medications in the Pipeline to Prevent MigraineReview: Depression Screening As Inpatient Important, FeasibleVitamin B6 Linked to Increased Risk of Hip Fracture2 Billion Worldwide Are Obese or OverweightPatient's Education Level May Be Key to Heart RiskMeds Rooted in Ancient China May Help Heart: ReviewBats Harbor Viruses That Could Cause Outbreaks in HumansExperimental Zika Vaccine Protects Mice Against Virus: StudyGlobal Climate Change Could Cause Rise in Airway IrritationEqual Wound Complications for Staples, Suture in Obese WomenDepression Can Slow Hospital Patients' Recovery: StudyEven Your Bones Can Get Fat, Mouse Study SuggestsNew Drugs Show Promise as First to Prevent Migraine1 in 7 Americans Has Kidney Disease: CDC
Questions and AnswersLinksBook Reviews
Related Topics

Several New Medications in the Pipeline to Prevent Migraine


HealthDay News
Updated: Jun 12th 2017

new article illustration

MONDAY, June 12, 2017 (HealthDay News) -- A host of new medications that appear to prevent migraine headaches are in the final stages of testing and approval in the United States, according to a presentation at the annual meeting of the American Headache Society, held from June 8 to 11 in Boston.

The new injectable drugs work by targeting calcitonin gene-related peptide (CGRP). One, erenumab, works by blocking the receptor CGRP acts on, while other drugs (fremanezumab by Teva; eptinezumab from Alder Biopharmaceuticals; and galcanezumab from Eli Lilly and Co.) work by blocking CGRP itself.

In one phase 3 trial funded by Amgen, nearly 1,000 patients with episodic migraine were randomly assigned to one of two doses of erenumab or placebo for six months. Half the patients receiving monthly injections of the higher dose of erenumab experienced a 50 percent reduction in number of migraines, Peter Goadsby, M.D., Ph.D., a professor of neurology at King's College London and the University of California, San Francisco, told HealthDay. In separate phase 2 trials testing erenumab's safety in chronic migraine patients, the medication was also tied to fewer attacks.

For the other three medications, researchers reported results of phase 2 trials that tested the drugs' safety. In each case, patients reported more headache-free days. Side effects, such as changes in blood pressure or potential liver damage, were found not to be a problem, researchers said. In addition, the drugs started working the first week of treatment. In some cases, patients were also able to cut back their other medications.

Funding from drug manufacturers was disclosed.

Press Release
Meeting Abstracts
More Information